🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in the Netherlands / NCT06384313
Recruiting Not applicable

Butyrate-enriched Triglyceride and Diabetes Prevention

NCT06384313 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2024-09-19
Last updated
2024-10-26

Condition(s) studied

Type 2 DiabetesPreDiabetesObesity

Investigational drug(s) / intervention(s)

butyrate/hexanoate-enriched triglycerides

butyrate/hexanoate-enriched triglycerides: The oils are consumed two times a day for 24 weeks (six months).

Study summary

A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control, inflammation, and insulin resistance. Even though the SCFA hexanoate is less researched, it has been shown to be involved in anti-inflammatory processes. Of note, acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation. It has been shown that a butyrate/hexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time. Yet, it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits. In this study it is hypothesized that a chronic increase of butyrate/hexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function, reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweight/obesity and prediabetes.

Eligibility

Sex
ALL
Min age
20 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Age 20-70 years * BMI ≥ 28 and \< 40 kg/m2 * Weight stable for at least 3 months * Normal blood pressure (systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg) * One or more of the following criteria to determine disturbed glucose/insulin homeostasis * Fasting glucose 5.6-6.9 mmol/L * Two-hour glucose of 7.8-11.1 mmol/L * HOMA-IR ≥ 2.2 * HbA1c (5.7-6.4%) Exclusion Criteria: * Diabetes mellitus (type 1 or 2) * Cardiovascular disease: including no history or myocardial infarction, heart failure, arrhythmias * Pulmonary disease: no history of chronic obstructive pulmonary disease, emphysema, bronchitis, asthma * Kidney (e.g. kidney failure) or liver (e.g. cirrhosis, non-alcoholic fatty acid) malfunction * Gastrointestinal disease (no inflammatory bowel disease, irritable bowel syndrome or digestive disorders) or a history of abdominal surgery (except appendectomy and cholecystectomy) * Autoimmune disease * Any other diseases affecting glucose and/or lipid metabolism or use of any medication that influence glucose or fat metabolism and inflammation * Ongoing disease or any disease with a life expectancy ≤ 5 years * Abuse of products; alcohol (\>15 units per week) and drugs, excessive nicotine use defined as \>20 cigarettes per week * Regular supplementation of pre- or probiotic products, use of pre- or probiotics, antibiotics and laxatives 3 months prior to the start of the study * Intensive exercise training more than three hours a week * Plan to lose weight or to follow a hypocaloric diet or vegetarian diet * Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Maastricht University Maastricht Limburg Recruiting

More Maastricht University Medical Center trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06384313 on ClinicalTrials.gov ↗ ← All trials in the Netherlands